Management of neonatal hyperbilirubinemia: interpretation of the clinical management guidelines drafted by the American Academy of Pediatrics and other countries
10.3760/cma.j.cn101070-20221022-01196
- VernacularTitle:新生儿高胆红素血症的管理
- Author:
Maojun LI
1
;
Binzhi TANG
;
Qing WU
;
Qian YANG
;
Xiaoming LIANG
;
Fulan ZOU
;
Rong HUANG
;
Changhui CHEN
Author Information
1. 四川省医学科学院·四川省人民医院儿科，成都 610072
- Keywords:
Infant, newborn;
Hyperbilirubinaemia;
Jaundice;
Management;
Guideline
- From:
Chinese Journal of Applied Clinical Pediatrics
2023;38(3):161-168
- CountryChina
- Language:Chinese
-
Abstract:
Neonatal hyperbilirubinaemia, clinically presenting as jaundice, is a ubiquitous and commonly a benign metabolic condition in newborn infants.It is a leading cause of hospitalization of neonates in the first week of life.Serum bilirubin has been considered as the most potent superoxide with the peroxyl radical scavenger activity.However, uncontrolled hyperbilirubinaemia or rapidly rising bilirubin can reach a neurotoxic concentration, potentially leading to central nervous system sequelae.Thus, the health status of jaundiced newborn infants is dependent on striking an appropriate balance between the protective effects of serum bilirubin and the risk of bilirubin neurotoxicity.In order to standardize the management of neonatal hyperbilirubinemia (jaundice), many countries have developed clinical practice management guidelines.This review sorted out and briefly interpreted the main contents of clinical management guidelines for neonatal hyperbilirubinemia drafted by the American Academy of Pediatrics and other countries, aiming to provide references of clinical diagnosis and treatment practice to domestic pediatrician.
